...Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients w/Inadequate Response to Conventional disease Modifying..

Printer-friendly versionSend by emailPDF version

Name

Eli Lilly and Company

Anticipated Amount

101 059.00

Activity Type

Clinical Trial

Award Type

Contract

Date

November 1, 2012 to May 30, 2014

Award Number

006122-00001

Sponsor Award Number

I4V-MC-JADX

Award Contacts

Name

Lisse,Jeffrey R

Title

Principal Investigator

Unit

Medicine

UA@Work is produced by University Communications

888 N. Euclid Ave., Ste. 413 (or) 
P.O. Box 210158, Tucson, AZ 85721

T 520.621.1877  F 520.626.4121

Feedback

2018 © The Arizona Board of Regents on behalf of the University of Arizona